Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transl Med. Jun 26, 2022; 10(1): 1-13
Published online Jun 26, 2022. doi: 10.5528/wjtm.v10.i1.1
Published online Jun 26, 2022. doi: 10.5528/wjtm.v10.i1.1
Current progress and emerging technologies for generating extrapancreatic functional insulin-producing cells
Md Aejaz Habeeb, Sandeep Kumar Vishwakarma, Safwaan Habeeb, Aleem Ahmed Khan, Centre for Liver Research and Diagnostics, Deccan College of Medical Sciences, Hyderabad 500058, Telangana, India
Author contributions: All the authors participated in literature search, manuscript writing and revision; Vishwakarma SK formatted the manuscript and designed figures; Habeeb MA provided clinical inputs; Khan AA supervised overall study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Md Aejaz Habeeb, MBBS, MD, DM, PhD, Centre for Liver Research and Diagnostics, Deccan College of Medical Sciences, Kanchanbagh, DMRL X Road, Hyderabad 500058, Telangana, India. aejazhabeeb@hotmail.com
Received: January 12, 2022
Peer-review started: January 12, 2022
First decision: February 8, 2022
Revised: March 5, 2022
Accepted: June 4, 2022
Article in press: June 4, 2022
Published online: June 26, 2022
Processing time: 163 Days and 0.9 Hours
Peer-review started: January 12, 2022
First decision: February 8, 2022
Revised: March 5, 2022
Accepted: June 4, 2022
Article in press: June 4, 2022
Published online: June 26, 2022
Processing time: 163 Days and 0.9 Hours
Core Tip
Core tip: The currently accepted available treatment strategies for uncontrolled diabetes mellitus (DM) are pancreas and islet transplantation. However, these strategies are limited due to unavailability of quality pancreas/islet donors, life-long need of immunosuppression, and associated complications. Exogenous insulin administration is one of the clinically established options for patients with type 1 DM. Liver could be an appropriate extrapancreatic source to isolate insulin-producing cells due to their similar embryonic developmental origin. The need to develop more effective diabetes cell-based therapies lies in the advancements of robust sensitive micro- and nanodevices for exogenous insulin delivery.